NSISBC.XD DXE
Novonesis (Novozymes) B
1W: -1.6%
1M: -7.6%
3M: -2.5%
YTD: +7.9%
1Y: -0.6%
kr 422.00 ($63.27)
+4.60 (+1.10%)
Weekly Expected Move ±3.1%
kr 391
kr 404
kr 417
kr 431
kr 444
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Balance Sheet Trends
Total Assets
$113.3B
+299.2% ▲
5Y CAGR: +40.9%
Total Liabilities
$30.0B
+113.5% ▲
5Y CAGR: +27.3%
Shareholders Equity
$83.4B
+496.3% ▲
5Y CAGR: +48.7%
Cash & Investments
$2.1B
+87.1% ▲
5Y CAGR: +24.0%
Total Debt
$13.4B
+72.2% ▲
5Y CAGR: +23.3%
Net Debt
$11.3B
+69.7% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $1.2B | $963M | $1.0B | $1.1B | $2.1B |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 |
| Cash & ST Investments | $1.2B | $963M | $1.0B | $1.1B | $2.1B |
| Net Receivables | $2.6B | $3.0B | $3.6B | $3.8B | $5.1B |
| Inventory | $2.4B | $3.0B | $3.8B | $3.6B | $5.4B |
| Other Current Assets | $814M | $880M | $618M | $947M | $1.4B |
| Total Current Assets | $6.9B | $7.8B | $9.2B | $9.5B | $14.0B |
| Property, Plant & Equip. | $9.6B | $10.2B | $12.1B | $12.3B | $22.1B |
| Goodwill & Intangibles | $2.6B | $5.0B | $4.7B | $4.5B | $74.8B |
| Long-Term Investments | $33M | $29M | $223M | $205M | $179M |
| Other Non-Current Assets | $1.4B | $1.7B | $1.7B | $1.9B | $2.2B |
| Total Non-Current Assets | $13.6B | $16.9B | $18.7B | $18.9B | $99.3B |
| Total Assets | $20.5B | $24.8B | $28.0B | $28.4B | $113.3B |
| — Liabilities — | |||||
| Accounts Payable | $1.1B | $1.5B | $1.9B | $1.6B | $3.2B |
| Short-Term Debt | $1.1B | $2.1B | $2.9B | $3.1B | $2.0B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $1.2B | $1.2B | $1.4B | $1.6B | $3.0B |
| Total Current Liabilities | $4.2B | $5.7B | $7.0B | $7.3B | $8.1B |
| Long-Term Debt | $3.2B | $3.7B | $3.6B | $4.3B | $11.4B |
| Other Non-Current Liab. | $1.5B | $2.8B | $2.9B | $2.2B | $10.4B |
| Total Non-Current Liabilities | $5.1B | $6.9B | $6.8B | $6.8B | $21.9B |
| Total Liabilities | $9.3B | $12.6B | $13.8B | $14.0B | $30.0B |
| — Equity — | |||||
| Common Stock | $570M | $564M | $562M | $562M | $937M |
| Retained Earnings | $11.3B | $11.3B | $13.1B | $13.8B | $82.3B |
| Accumulated OCI | -$600M | -$40M | $213M | -$339M | $134M |
| Total Stockholders Equity | $11.2B | $11.8B | $13.8B | $14.0B | $83.4B |
| Total Liabilities & Equity | $20.5B | $24.8B | $28.0B | $28.4B | $113.3B |
| — Key Metrics — | |||||
| Total Debt | $4.9B | $6.3B | $6.9B | $7.8B | $13.4B |
| Net Debt | $3.6B | $5.2B | $5.8B | $6.7B | $11.3B |
| Total Investments | $33M | $29M | $223M | $205M | $179M |